Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 12660932.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A prospective, open-label study was conducted to assess the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected patients experiencing viral rebound while receiving therapy with nelfinavir-containing regimens, to determine whether the protease genotype influenced the outcome of the salvage regimen. Genotyping from 29 nelfinavir failures revealed D30N in 17 (59%) and L90M in 11 (38%) cases. Suppression to <400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus.
Medical subject headings
- Adenine
- HIV Infections
- Indinavir
- Nelfinavir
- Organophosphonates
- Oxazines